SOURCE: BioProgress PLC

June 07, 2005 02:01 ET

BioProgress plc announces Update on FMC / Wyeth

Cambridgeshire -- (MARKET WIRE) -- June 7, 2005 --

Press Release                                               7 June 2005

                             BioProgress plc

                    ("BioProgress" or "the Company")

                   Update on partnership developments

BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery mechanisms for the pharmaceutical oral dosage markets, today announces a progress update on partnership developments.

BioProgress is delighted to announce that the first NROBE™ machine for powder encapsulation has been delivered to its strategic partner FMC BioPolymer ("FMC"), a business unit of the FMC Corporation (NYSE: FMC). This is a significant step in the development of the technology, leading towards full scale production. BioProgress will continue its close collaboration with FMC to maximise the commercial potential of NROBE™.

The global market for oral dose forms is worth several billion US$ and NROBE™ presents a unique delivery solution to this market. FMC BioPolymer is a global leader in the supply of products and services to the pharmaceutical and life sciences industries.

FMC Corporation (NYSE: FMC) is a diversified chemical company serving agricultural, industrial and consumer markets globally for more than a century with innovative solutions, applications and quality products. The company employs approximately 5,500 people throughout the world. The company divides its businesses into three segments: Agricultural Products, Speciality Chemicals and Industrial Chemicals.

BioProgress also advises that the exclusive option agreement with Wyeth will not be extended. BioProgress will continue to explore opportunities with Wyeth. However, in relation to the Company's SWOLLO liquid-fill encapsulation technology, BioProgress will extend this exciting technology to other partners so as to fully exploit and commercialise its potential.

                                    - Ends -

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company's filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

 BioProgress plc
 Richard Trevillion, CEO                        Tel: +44 (0) 1354 655674
 Dan Farrow, FD                            

UK Media enquiries:
 Samantha Robbins / Henry Harrison-Topham      Tel: +44 (0) 20 7398 7700    

US Investor enquiries:
 Taylor Rafferty
 Andrew Saunders                                    Tel: +1 212 889 4350   

                  This information is provided by RNS
     The company news service from the London Stock Exchange